China Small Molecule CDMO Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Active Pharmaceutical Ingredients (API), Finished Drug Products), By Drug (Innovators, Generics), By Application (Oncology, Cardiovascular Disease), And Segment Forecasts

Table of Contents

Chapter 1. Research Methodology and Scope
                   1.1. Market Segmentation & Scope
                   1.2. Segment Definitions
                       1.2.1. Product
                       1.2.2. Drug
                       1.2.3. Application
                   1.3. Research Methodology
                   1.4. Information Procurement
                       1.4.1. Purchased Database
                       1.4.2. GVR’s Internal Database
                       1.4.3. Secondary Sources
                       1.4.4. Primary Research
                   1.5. Information Or Data Analysis
                       1.5.1. Data Analysis Models
                   1.6. Market Formulation & Validation
                   1.7. Model Details
                       1.7.1. Commodity Flow Analysis
                       1.7.2. Value-Chain-Based Sizing & Forecasting
                       1.7.3. Multivariate Model Analysis
                   1.8. List Of Secondary Sources
                   1.9. List Of Abbreviations
                   1.10. Objectives
Chapter 2. Executive Summary
                   2.1. Market Outlook
                   2.2. Segment Outlook
                   2.3. Competitive Insights
Chapter 3. China Small Molecule CDMO Market Variables, Trends & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent Market Outlook
                       3.1.2. Related/Ancillary Market Outlook
                   3.2. Market Dynamics
                       3.2.1. Market Driver Analysis
                           3.2.1.1. Rise in drug development pipelines
                           3.2.1.2. Growing reliance on CDMOS for cost-effective and specialized manufacturing services.
                           3.2.1.3. Capacity expansions by CDMOS
                           3.2.1.4. Technological advancements
                       3.2.2. Market Restraint Analysis
                           3.2.2.1. Growing demand for biologics
                           3.2.2.2. Complexity and challenges in the synthesis of certain small molecules, impacting manufacturing efficiency
                   3.3. Technology Landscape
                   3.4. Market Analysis Tools
                       3.4.1. Porter’s Five Force Analysis
                       3.4.2. PESTEL by SWOT Analysis
                       3.4.3. COVID-19 Impact Analysis
Chapter 4. China Small Molecule CDMO Market: Product Estimates & Trend Analysis
                   4.1. Segment Dashboard
                   4.2. China Small Molecule CDMO Market Product Movement Analysis
                   4.3. China Small Molecule CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
                   4.4. Active Pharmaceutical Ingredients (API)
                       4.4.1. Active Pharmaceutical Ingredients (API) Market Estimates and Forecasts,2021 - 2033 (USD Million)
                   4.5. Finished Drug Products
                       4.5.1. Finished Drug Products Market Estimates and Forecasts,2021 - 2033 (USD Million)
Chapter 5. China Small Molecule CDMO Market: Drug Estimates & Trend Analysis
                   5.1. Segment Dashboard
                   5.2. China Small Molecule CDMO Market Drug Movement Analysis
                   5.3. China Small Molecule CDMO Market Size & Trend Analysis, by Drug, 2018 to 2030 (USD Million)
                   5.4. Innovators
                       5.4.1. Innovators Market Estimates and Forecasts,2021 - 2033 (USD Million)
                   5.5. Generics
                       5.5.1. Generics Market Estimates and Forecasts,2021 - 2033 (USD Million)
Chapter 6. China Small Molecule CDMO Market: Application Estimates & Trend Analysis
                   6.1. Segment Dashboard
                   6.2. China Small Molecule CDMO Market Application Movement Analysis
                   6.3. China Small Molecule CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
                   6.4. Oncology
                       6.4.1. Oncology Market Estimates and Forecasts,2021 - 2033 (USD Million)
                   6.5. Cardiovascular Disease
                       6.5.1. Cardiovascular Disease Market Estimates and Forecasts,2021 - 2033 (USD Million)
                   6.6. Central Nervous System (CNS) Conditions
                       6.6.1. Central Nervous System (CNS) Conditions Market Estimates and Forecasts,2021 - 2033 (USD Million)
                   6.7. Autoimmune/Inflammation
                       6.7.1. Autoimmune/Inflammation Market Estimates and Forecasts,2021 - 2033 (USD Million)
                   6.8. Others
                       6.8.1. Others Market Estimates and Forecasts,2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
                   7.1. Market Participant Categorization
                   7.2. Company Market Share/Assessment Analysis, 2024
                   7.3. Company Profiles
                       7.3.1. Lonza
                           7.3.1.1. Company Overview
                           7.3.1.2. Financial Performance
                           7.3.1.3. Service Benchmarking
                           7.3.1.4. Strategic Initiatives
                       7.3.2. Catalent, Inc
                           7.3.2.1. Company Overview
                           7.3.2.2. Financial Performance
                           7.3.2.3. Service Benchmarking
                           7.3.2.4. Strategic Initiatives
                       7.3.3. Thermo Fisher Scientific Inc.
                           7.3.3.1. Company Overview
                           7.3.3.2. Financial Performance
                           7.3.3.3. Service Benchmarking
                           7.3.3.4. Strategic Initiatives
                       7.3.4. Bellen Chemistry
                           7.3.4.1. Company Overview
                           7.3.4.2. Financial Performance
                           7.3.4.3. Service Benchmarking
                           7.3.4.4. Strategic Initiatives
                       7.3.5. Siegfried Holding AG
                           7.3.5.1. Company Overview
                           7.3.5.2. Financial Performance
                           7.3.5.3. Service Benchmarking
                           7.3.5.4. Strategic Initiatives
                       7.3.6. Recipharm AB
                           7.3.6.1. Company Overview
                           7.3.6.2. Financial Performance
                           7.3.6.3. Service Benchmarking
                           7.3.6.4. Strategic Initiatives
                       7.3.7. Eurofins Scientific
                           7.3.7.1. Company Overview
                           7.3.7.2. Financial Performance
                           7.3.7.3. Service Benchmarking
                           7.3.7.4. Strategic Initiatives
                       7.3.8. WuXi AppTec
                           7.3.8.1. Company Overview
                           7.3.8.2. Financial Performance
                           7.3.8.3. Service Benchmarking
                           7.3.8.4. Strategic Initiatives
                       7.3.9. Asymchem Laboratories
                           7.3.9.1. Company Overview
                           7.3.9.2. Financial Performance
                           7.3.9.3. Service Benchmarking
                           7.3.9.4. Strategic Initiatives
                       7.3.10. Langhua Pharmaceutical (Viva Biotech subsidiary)
                           7.3.10.1. Company Overview
                           7.3.10.2. Financial Performance
                           7.3.10.3. Service Benchmarking
                           7.3.10.4. Strategic Initiatives
                       7.3.11. Apeloa Pharmaceutical
                           7.3.11.1. Company Overview
                           7.3.11.2. Financial Performance
                           7.3.11.3. Service Benchmarking
                           7.3.11.4. Strategic Initiatives
                       7.3.12. JiuZhou Pharmaceutical
                           7.3.12.1. Company Overview
                           7.3.12.2. Financial Performance
                           7.3.12.3. Service Benchmarking
                           7.3.12.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 China Small Molecule CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
Table 4 China Small Molecule CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
Table 5 China Small Molecule CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 China Small Molecule CDMO Market segmentation
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot 1
Fig. 14 Segment snapshot 2
Fig. 15 Competitive landscape snapshot
Fig. 16 Market Dynamics
Fig. 17 Porter’s five force analysis
Fig. 18 PESTEL analysis
Fig. 19 China Small Molecule CDMO Market: Product outlook key takeaways
Fig. 20 China Small Molecule CDMO Market: Product movement analysis
Fig. 21 Active Pharmaceutical Ingredients (API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 22 Finished Drug Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 23 China Small Molecule CDMO Market: Drug outlook key takeaways
Fig. 24 China Small Molecule CDMO Market: Drug movement analysis
Fig. 25 Innovators Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 26 Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 27 China Small Molecule CDMO Market: Application outlook key takeaways
Fig. 28 China Small Molecule CDMO Market: Application movement analysis
Fig. 29 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 30 Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 31 Central Nervous System (CNS) Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 32 Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 33 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Fig. 34 Market participant categorization
Fig. 35 China Small Molecule CDMO market position analysis, 2024
Fig. 36 Strategic framework